AZTR

4 - Azitra, Inc. (0001701478) (Issuer)

4 - Azitra, Inc. (0001701478) (Issuer)

4 - Azitra, Inc. (0001701478) (Issuer)

8-K - Azitra, Inc. (0001701478) (Filer)

4 - Azitra, Inc. (0001701478) (Issuer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As previously reported, on Octobe

DEFA14A - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026. About AzitraAzitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12,

BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update. FY 2025 and Recent Business HighlightsInitiated Phase 1/2 Trial for ATR-04 program targeting oncology patients with EGFRi-associated rash; presented ATR-04 trial design and update at ASCO 2025Announced positive preclinical data for ATR-01 program, targeting the treatment of ichth

8-K - Azitra, Inc. (0001701478) (Filer)

10-K - Azitra, Inc. (0001701478) (Filer)

MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestonesBRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.

BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EG

DEFA14A - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the U.S. Securities and Exchange Commission (the "SEC") on January 2, 2026 (the "Special Meeting Proxy Statement") becau

S-8 - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Jan. 7, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at Biotech Showcase™ taking place in San Francisco, January 12-14, 2026. During the event, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's clinical development strategy, recent corporate achievements, and anticipated milestones. Details are as follows: E

DEF 14A - Azitra, Inc. (0001701478) (Filer)

PRE 14A - Azitra, Inc. (0001701478) (Filer)

4 - Azitra, Inc. (0001701478) (Issuer)

4 - Azitra, Inc. (0001701478) (Issuer)

4 - Azitra, Inc. (0001701478) (Issuer)